|
|
News Breaks | | | | June 8, 2012 | | 07:37 EDT |  | GILD | Gilead risk/reward ratio positive, says RBC Capital
RBC Capital believes that Gilead has the greatest potential to develop a simple, all-oral HCV regimen with sales potential of $3B-$5B. The firm sees several upcoming catalysts for the stock and expects it to appreciate into 2013. RBC Capital identifies the stock as its best large cap risk/reward idea and maintains an Outperform rating on the shares. | |
|
News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. |
|
|
| May 24, 2013 | | 07:20 EDT | | GILD | Celgene, Gilead, and Biogen could go much higher, says Bernstein
 Subscribe for More Information | | | May 23, 2013 | | 10:27 EDT |  | GILD | Gilead has a conference call hosted by JPMorgan
Subscribe for More Information | | | May 21, 2013 | | 16:51 EDT |  | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
Subscribe for More Information | | | May 20, 2013 | | 07:34 EDT | | GILD | UBS to host a conference
Subscribe for More Information | | | May 16, 2013 | | 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | | | May 15, 2013 | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | May 13, 2013 | | 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR | |
|
|
|
|
|
|
